Investor Presentation
Attractive market fundamentals | Leadership and scale | Multiple growth drivers Margin improvement | Attractive financial outlook | Compelling sustainability story
Multiple drivers to deliver mid-single digit top-line growth¹
in the mid-term
Expanding
breadth
and depth
of pipeline
Additional
M&A activity
E
D
C
B
Leveraging
A
Maximizing
Improving
product mix
strategic
partnerships
Sales
execution
near-term
Biosimilars
launches
Mid-single digit net sales growth¹ in the mid-term (2028)
Included in business plan
1. In constant currencies. For additional information regarding constant currencies, which is a non-IFRS measure, see "Appendix" starting on slide 31
11
Management Presentation
Incremental growth
Upside to business plan
SANDOZView entire presentation